FDA Brief

Warning letters Drugs

FDA warning letter to

CBD Social

High riskIssued Mar 28, 2022Posted Mar 29, 2022Center for Drug Evaluation and Research | CDER

FDA and FTC warn CBD Social over website claims that CBD products prevent or treat COVID-19.

What happened

FDA reviewed the website on February 17, 2022, and FTC reviewed it on March 15, 2022. The agencies found CBD products offered for sale with claims that they mitigate, prevent, treat, diagnose, or cure COVID-19. FDA says this makes the products unapproved new drugs and misbranded drugs.

What FDA found

  1. The website claims CBD products mitigate, prevent, treat, diagnose, or cure COVID-19, so FDA treats them as unapproved new drugs.

    FD&C Act section 505(a), 21 U.S.C. § 355(a)
  2. The products are misbranded, meaning their labeling is false or misleading, because the labeling includes misleading COVID-19 claims.

    FD&C Act section 502, 21 U.S.C. § 352
  3. The company is prohibited from introducing these products into interstate commerce.

    FD&C Act sections 301(a) and (d), 21 U.S.C. § 331(a) and (d)
  4. FTC says the company advertised that its products prevent, treat, or cure disease without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. § 41 et seq.
  5. FTC says deceptive COVID-19 treatment, cure, prevention, or mitigation claims can lead to civil penalties under the COVID-19 Consumer Protection Act.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA tells CBD Social to take immediate action to stop selling unapproved products for COVID-19 and, within 48 hours, to email COVID-19-Task-Force-CDER@fda.hhs.gov with the steps taken and related documentation. FDA also tells the company to review its websites, labels, and promotional materials to remove misleading COVID-19 claims.

Who should pay attention

  • CBD brands and retailers that make health claims
  • companies selling COVID-19-related products online
  • marketers of unapproved drugs or supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Medolife Rx D/B/A MedoLife Corp., AELIA, Inc. and Quanta Inc.

    FDA says Medolife sold unapproved Escozine drugs online with claims to treat cancer, HIV, and COVID-19.

    High risk
  2. www.ivermectin4covid.com

    FDA warned website ivermectin4covid.com for selling unapproved, misbranded ivermectin drugs claiming COVID-19 use.

    High risk
  3. Medical Mikes, Inc.

    FDA and FTC warned Medical Mikes over unapproved CBD claims to prevent or treat COVID-19.

    High risk
  4. Purecraft LLC

    FDA and FTC warn Purecraft LLC over CBD products marketed with unapproved COVID-19 prevention and treatment claims.

    High risk